Vrije Universiteit Brussel

Belgium’s Ingmar De Vos elected unanimously as President of the Association of Summer Olympic International Federations

Retrieved on: 
Tuesday, April 9, 2024
RSA, FEI, International Olympic Committee, AZE, EEF, Trust, United, International, United Nations, Diversity, Summer, Executive Committee, Gender equality, Vrije Universiteit Brussel, Legal Affairs, Sports governing body, IOC, Pleasure, Master, GBR, Heart, Gender, Senate, WADA, BEL, Real estate

BIRMINGHAM, United Kingdom, April 09, 2024 (GLOBE NEWSWIRE) -- Belgium’s Ingmar De Vos, who has served as the FEI President since 2014, has been elected unanimously as the new President of the Association of Summer Olympic International Federations (ASOIF). The election took place today, 9 April 2024, at the 48th ASOIF General Assembly held in Birmingham (GBR) during the SportAccord World Sport and Business Summit. Ingmar De Vos ran unopposed and was elected by secret ballot for a term of four years. He will take up his new position on 1 January 2025.

Key Points: 
  • BIRMINGHAM, United Kingdom, April 09, 2024 (GLOBE NEWSWIRE) -- Belgium’s Ingmar De Vos, who has served as the FEI President since 2014, has been elected unanimously as the new President of the Association of Summer Olympic International Federations (ASOIF).
  • “I am humbled by today’s result and would like to express my deep gratitude to the Summer Olympic International Federations for their trust,” the newly elected ASOIF President Ingmar De Vos said.
  • “On behalf of the International Olympic Committee, I would like to extend my heartfelt congratulations to Ingmar De Vos on his election as ASOIF President,” IOC President Thomas Bach commented.
  • Since 2016, he has been a member of the Association of Summer Olympic International Federations (ASOIF) Governance Taskforce.

AI Audits, Equity Awareness in Data Privacy Methods, and Facial Recognition Technologies are Major Topics During This Year’s Privacy Papers for Policymakers Events

Retrieved on: 
Tuesday, April 2, 2024
Transfer, Law school, Artificiality, Public, Facial recognition, University of Groningen, Vrije Universiteit Brussel, LLM, Justice, United States Senate, Safe, Policy, Legislation, FGV, Harm, Microsoft, Employment, Congress, Microsoft Research, Universidad de Montevideo, Risk, Democracy, Facial recognition system, Future, Urban, Legislative assistant, Urban Institute, Privacy, Rochester Institute of Technology, Senate, FPF, ETH Zurich, Forecasting, Internet, Trust (social science), Research, AI, University, Private sector, Personal data, Student, Model, Use, Paper, Information, Element, Algorithm, Upturn, Barnard College, Columbia University, Housing, Government, Salvador Allende, Cryptocurrency

Author: Judy Wang, Communications Intern, FPF The Future of Privacy Forum (FPF) hosted two engaging events honoring 2023’s must-read privacy scholarship at the 14th Annual Privacy Papers for Policymakers ceremonies. On Tuesday, February 27, FPF hosted a Capitol Hill event featuring an opening keynote by U.S. Senator Peter Welch (D-VT) as well as facilitated discussions [?]

Key Points: 


Author: Judy Wang, Communications Intern, FPF The Future of Privacy Forum (FPF) hosted two engaging events honoring 2023’s must-read privacy scholarship at the 14th Annual Privacy Papers for Policymakers ceremonies. On Tuesday, February 27, FPF hosted a Capitol Hill event featuring an opening keynote by U.S. Senator Peter Welch (D-VT) as well as facilitated discussions [?]

EQS-News: Enapter AG continues its successful development in 2024 with numerous new orders

Retrieved on: 
Wednesday, March 13, 2024
Nexus, AEM, Electrolysis, Natural gas, Vrije Universiteit Brussel, Hydrogen, CO2

Orders totalling more than 250 AEM Electrolysers EL 4 from the USA, Belgium, India and Germany

Key Points: 
  • Orders totalling more than 250 AEM Electrolysers EL 4 from the USA, Belgium, India and Germany
    Berlin, February 20, 2024.
  • Enapter AG (ISIN: DE000A255G02) is seamlessly continuing its good 2023 performance in the 2024 financial year and has recorded numerous new orders for the delivery of its AEM Electrolysers EL 4.
  • Enapter also continues to see strong demand for its megawatt-class devices for the production of hydrogen on an industrial scale.
  • We have received inquiries and concrete orders from new customers as well as follow-up orders from our existing partner network, which now comprises over 180 partners worldwide.

Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping

Retrieved on: 
Tuesday, January 23, 2024
Research, Radboud University Medical Center, DNA, Workflow, Genomics, Graphics processing unit, Doctor of Philosophy, OGM, NVIDIA, Computing, Data analysis, Vrije Universiteit Brussel, Video game

Stratys is the next evolution of OGM, with significantly and impressively improved throughput.

Key Points: 
  • Stratys is the next evolution of OGM, with significantly and impressively improved throughput.
  • This scalability aligns nicely with recently achieved automated lab workflow for DNA isolation and improved automated analysis and reporting through VIA™ software.
  • Smart design also allows higher flexibility and faster processing per sample when compared to the Saphyr system.
  • We are excited to see these early access sites partner with us as we extend Stratys adoption across the world.”

UZ Brussel PERT and Aidoc Pave the Way as First Hospital in Europe for Expedited Treatment of Pulmonary Embolism with AI

Retrieved on: 
Thursday, October 26, 2023
Intelligence, Radiology, UZB, Physician, PERT, Acquisition, Health, Vrije Universiteit Brussel, Pulmonary embolism, PE, Hospital, CT, Embolism, AI, Patient, Diagnosis, Communication, Medical imaging, Medical device, Aidoc

LONDON, Oct. 26, 2023 /PRNewswire/ -- Aidoc today announced a pioneering collaboration with the Pulmonary Embolism Response Team (PERT) at UZ Brussel (UZB), becoming the first European hospital to use AI for cross-departmental care coordination, expediting treatment for suspected pulmonary embolism (PE) patients. Aidoc automatically flags suspected positive cases of PE and sends an automatic alert to UZ Brussel's Pulmonary Embolism Response Team (PERT), allowing for fast multidisciplinary decision-making and rapid delivery of life-saving treatment.

Key Points: 
  • Aidoc automatically flags suspected positive cases of PE and sends an automatic alert to UZ Brussel's Pulmonary Embolism Response Team (PERT), allowing for fast multidisciplinary decision-making and rapid delivery of life-saving treatment.
  • Pulmonary embolism is the third most common acute cardiovascular syndrome, resulting from a blood clot obstructing a lung artery, and can be swiftly fatal without prompt diagnosis and treatment.
  • "We are thrilled about our ongoing collaboration with Aidoc," states Marc Noppen, CEO of UZ Brussel.
  • "This innovative approach not only enhances patient care but also sets the stage for a promising future of AI-driven healthcare across Europe."

TAWANI Foundation Gifts Over $1.3M to the SETI Institute and the Field Museum in Honor of Earth Day

Retrieved on: 
Thursday, April 20, 2023
Field Museum of Natural History, Swiss, Swiss Federal Institute of Technology, Vrije Universiteit Brussel, Solar System, University, Prevalence, Life, SETI Institute, Exploration, Face, Ames Research Center, Geological Survey of India, Intelligence, Research, Pritzker family, History, Entomology, University of Innsbruck, SETI, Geology, Planet, RET, Knowledge, Cosmic dust, Environment, Swiss Federal Institute of Aquatic Science and Technology, Pharmaceutical industry, Rare-earth element, Silicon, Meteoritics

Chicago, April 20, 2023 (GLOBE NEWSWIRE) -- The TAWANI Foundation announces its commitment of $1.3M to the SETI Institute and continued support for the Robert A. Pritzker Center for Meteoritics and Polar Studies at the Field Museum in honor of Earth Day.

Key Points: 
  • Chicago, April 20, 2023 (GLOBE NEWSWIRE) -- The TAWANI Foundation announces its commitment of $1.3M to the SETI Institute and continued support for the Robert A. Pritzker Center for Meteoritics and Polar Studies at the Field Museum in honor of Earth Day.
  • This year, the Institute’s Anthropo Snow Project will receive $210,000, the first installment of a three-year gift totaling $630,000.
  • Heck serves as curator of Meteoritics and Polar Studies and senior director of research at the Field Museum.
  • “We are proud to support these and other paleoenvironmental studies this Earth Day and beyond.”
    To learn more about TAWANI Foundation grants, visit www.tawanifoundation.org/our-grants .

Brussels Privacy Symposium 2022 Report

Retrieved on: 
Tuesday, March 21, 2023
People, FPF, Survivor, University of Colorado Boulder, International Observatory of Human Rights, Vrije Universiteit Brussel, University, European Data Protection Supervisor, BPH, Privacy, Future of Privacy Forum, Symposium (Plato), Hansot, CEO, EDPS, Associate, Future, LGPD, VUB, Leiden, Symposium, Global Privacy Enforcement Network, GDPR, Bias, Medical device, Management, Charles Chaynes

Brussels Privacy Symposium 2022 Report

Key Points: 
  • Brussels Privacy Symposium 2022 Report
    On November 15, 2022, the Future of Privacy Forum (FPF) and the Brussels Privacy Hub (BPH) of Vrije Universiteit Brussel (VUB) jointly hosted the sixth edition of the Brussels Privacy Symposium on the topic of “Vulnerable People, Marginalization, and Data Protection.” Participants explored the extent to which data protection and privacy law including the EU’s General Data Protection Regulation (GDPR) and other data protection laws like Brazil’s General Data Protection Law (LGPD) safeguard and empower vulnerable and marginalized people.
  • Participants also debated balancing the right to privacy with the need to process sensitive personal information to uncover and prevent bias and marginalization.
  • The event also marked the launch of VULNERA, the International Observatory on Vulnerable People in Data Protection, coordinated by the Brussels Privacy Hub and the Future of Privacy Forum.
  • This Report outlines some of the most noteworthy points raised by the speakers during the day-long Symposium.

Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitropin delta) at the Congress of the Pacific Society for Reproductive Medicine

Retrieved on: 
Monday, March 13, 2023
Health, Pharmaceutical, Woman, IVF, Phase 3, Research, Contraindication, OS, ADR, Senior, Pregnancy, Maternal health, Reproductive medicine, Ferring Pharmaceuticals, GRAPE, OHSS, RCT 1, Observational study, Patient, Pregnancy rate, Congress, Frontiers in Endocrinology, PSRM, Ovarian hyperstimulation syndrome, Adverse drug reaction, Isabella Tree, Safety, Vrije Universiteit Brussel, Incidence, ICSI, Physician, Pacific Society for Reproductive Health Trust, AMH, Oocyte, Pharmaceutical industry, Birth control, Gonadotropin preparations, Endocrinology

Today, an oral poster of the first post-authorisation Phase 4 real-world study, PROFILE, is being presented at the 13th Congress of the Pacific Society for Reproductive Medicine (PSRM) 2023 in Australia.

Key Points: 
  • Today, an oral poster of the first post-authorisation Phase 4 real-world study, PROFILE, is being presented at the 13th Congress of the Pacific Society for Reproductive Medicine (PSRM) 2023 in Australia.
  • Results highlighted that with Rekovelle, almost three-quarters (74.0%) of women had between 4-19 oocytes retrieved and 255 women (27.0%) achieved an ongoing pregnancy at 10-11 weeks after transfer.
  • Adverse drug reactions (ADRs) were monitored for all initiated OS cycles, and the number of ADRs leading to treatment and study discontinuation was low (n=4).
  • “Ferring is committed to building healthy families of every shape and size by developing innovative fertility treatments.

Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor

Retrieved on: 
Wednesday, January 25, 2023
Master of Science, COVID-19, Arrowhead Pharmaceuticals, Deloitte Technology Fast 500, Trustee, Woman, Health care, Erasmus University Rotterdam, The Advisory Board Company, Magazin, Bluerock Creek, Pharmaceutical Research and Manufacturers of America, Popular Executive Committee of Valencia, Business development, Harvard Business Review, Johnson & Johnson, Doctor of Philosophy, Executive Committee, Biotechnology Innovation Organization, Science, Biogen, Infection, Retirement, American City Business Journals, Therapy, MBA, Molecular biology, Vrije Universiteit Brussel, Overseer, IEEE Medal for Innovations in Healthcare Technology, Patient, Silicon, Growth, University, Management, Pharmaceutical industry, Biotechnology, Coronavirus, Biochemistry, Exelixis, Engineering, Ghent University, Bayer

SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023. The Company’s Board of Directors has appointed industry veteran Marianne De Backer, MSc, Ph.D., MBA, currently Executive Vice President, Head of Pharmaceuticals Strategy, Business Development and Licensing/Open Innovation, and Member of the Executive Committee for Bayer Pharmaceuticals, as his successor, effective April 3, 2023. She will also join Vir’s Board of Directors.

Key Points: 
  • “George led the Company through a period of significant transformation, accelerated its growth and established a broad pipeline and strategy that we believe will support our long-term success.
  • In 2022, Vir was named the fastest growing company on the 2022 Deloitte Technology Fast 500 .
  • Prior to joining Vir, Dr. Scangos served as CEO and as a member of the Board of Biogen Inc. for six years.
  • “Vir represents an amalgamation of the best of what science and commitment to patients have to offer.

Confo Therapeutics’ Scientific Founder Jan Steyaert Receives Prestigious Gabbay Award for Contributions to Structural Biology

Retrieved on: 
Friday, October 28, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Neuropathic pain, Drug discovery, Doctor of Philosophy, Trial of the century, Neurodegeneration, Coronavirus Scientific Advisory Board (Turkey), CEO, Vrije Universiteit Brussel, Harold, Patient, Technology, Industry, Research, Therapy, Brandeis University, Â, II, Medicine, Jacob, Pharmaceutical industry, G protein-coupled receptor, Camelidae, Ageing

Confo Therapeutics , a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor Jan Steyaert, PhD, has been selected as the recipient of the Jacob and Louise Gabbay Award.

Key Points: 
  • Confo Therapeutics , a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor Jan Steyaert, PhD, has been selected as the recipient of the Jacob and Louise Gabbay Award.
  • Professor Steyaert is the 24th scientist to receive the award and the first Belgian recipient.
  • We congratulate Jan on the award and the well-deserved recognition for his pioneering work, said Cedric Ververken, CEO of Confo Therapeutics.
  • Co-founded by Professor Steyaert, Confo Therapeutics utilizes the Confo technology which consists of single domain antibodies that transform unstable GPCRs into stable functional conformations, thereby facilitating drug discovery research for the creation of disruptive therapeutics.